Yeast Mash Exosome Composition for Cancer Inhibition and Skin Elasticity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies have not effectively utilized yeast mash and aged miso as sources of exosomes for medical and cosmetic applications, particularly for cancer suppression, tissue elasticity maintenance, and immune system enhancement.
Innovation Solution
Exosomes are extracted from yeast mash and aged miso using a unique production method, which involves centrifugation and ultracentrifugation, and are used in compositions for health maintenance, cancer treatment, and cosmetic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If small molecules or peptides are used as drug candidates, then synthesis and purification are easier, but binding affinity to G protein-coupled receptors is insufficient
Solution Approach 1:
The patent uses composite materials by combining a peptide framework with small molecule pharmacophores. The peptide portion provides binding affinity through interaction with G protein-coupled receptors, while the attached small molecule moiety contributes additional binding interactions and pharmacological activity. This composite approach resolves the contradiction by achieving both ease of synthesis (using modular peptide coupling) and sufficient binding affinity (through combined interaction modes).
Solution Approach 2:
The invention creates multi-functional compounds where a single molecule simultaneously exhibits peptide-like binding characteristics and small molecule pharmacological properties. The hybrid structure allows the compound to interact with G protein-coupled receptors through multiple mechanisms, achieving both high binding affinity and ease of manufacture through standardized peptide synthesis protocols.
2Reliability
If antibodies are used as drug candidates, then binding affinity to targets is high, but production cost and complexity increase
Solution Approach 1:
The patent segments the binding function by dividing the molecular structure into distinct functional regions: a peptide portion that interacts with the receptor and a small molecule moiety that provides pharmacological activity. This segmentation allows each component to be optimized independently and simplifies synthesis compared to producing full antibodies, reducing production complexity while maintaining binding affinity.
Solution Approach 2:
The hybrid peptide-small molecule compound acts as an intermediary between the target receptor and the desired pharmacological effect. It provides a simplified alternative to antibody-based therapy, achieving high binding affinity through the peptide component while avoiding the production complexity of full antibodies through modular small molecule attachment.
3Ease of manufacture
If conventional small molecules are used, then production is simple, but they cannot effectively interact with G protein-coupled receptors
Solution Approach 1:
The invention creates composite molecules that combine peptide and small molecule characteristics. The peptide portion provides the necessary structural features for G protein-coupled receptor interaction, while the attached small molecule maintains production simplicity through standardized coupling methods. This composite structure enables effective receptor interaction while preserving manufacturing advantages.
Solution Approach 2:
The patent changes the molecular parameters by transitioning from conventional small molecules to hybrid peptide-small molecule structures. This parameter change enables the compound to interact with G protein-coupled receptors through extended interaction surfaces provided by the peptide component, while the small molecule attachment maintains production simplicity through established synthetic methodologies.
Data Source
Figure 1
Figure 2A~2B
Figure 3
AI summary
An object of the present invention is to prepare a novel food-derived exosome composition and to provide a cancer inhibitor or an agent for preventing decrease in tissue elasticity or an agent for improving elasticity containing a novel active ingredient. As a result of intensive studies on the purification process, the inventors have found that an exosome can be extracted from yeast mash and moromi by a unique production method. The inventors have found that the exosome recovered from the yeast mash and the moromi has a cancer cell proliferation inhibition ability, an ability to promote increase in the amount of granzyme, and an ability to promote expression of collagen and elastin. Accordingly, the inventors provide a composition for treating or preventing cancer and an agent for preventing decrease in tissue elasticity or an agent for improving elasticity, containing exosomes derived from yeast mash and moromi of sake.